Exploring Optimal Treatment for Patients With STK-11– and KEAP-1–Mutated Lung Cancer
Featuring Balazs Halmos, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Balazs Halmos MD, Montefiore Einstein Comprehensive Cancer Center, discussed the use of CTLA-4 inhibition in the treatment of STK-11– and KEAP-1–mutated lung cancers.
Dr Halmos concluded that, while the addition of CTLA-4 inhibition in the treatment of STK-11 and KEAP-1 mutated lung cancers demonstrates possible disease improvement, further data needs to be collected to confirm potential progress.
Source:
Halmos, B. Debate: STK11 and Associated Biomarkers: Ready for Primetime or Need More Time? - Need More Time. Presented at Great Debates & Updates in Lung Cancer; April 27-28, 2024; New York, NY.
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of OLN or HMP Global, their employees, and affiliates.
